

User testing to inform modification of the MyHealthyGut digital health application in inflammatory bowel disease

Madeline Erlich, RD^{1,2}; Sarah Lindblad³, RD; Natasha Haskey, RD⁴, PhD; Darlene Higbee
Clarkin⁵; Taojie Dong⁶; Ruth Harvie, RD, PhD⁷; Genelle Lunken, RD, PhD⁸⁻⁹; Jess Pirnack, RD¹⁰;
Kevan Jacobson, MD⁸⁻⁹

Affiliations:

¹Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

²Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada

³Royal Victoria Regional Health Centre, Barrie, Ontario, Canada

⁴Department of Biology, Irving K Barber Faculty of Science, University of British Columbia, Okanagan, Kelowna, British Columbia, Canada

⁵KORE Digital Health Therapeutics Inc., Vancouver, British Columbia, Canada

⁶ Faculty of Land and Food Systems, University of British Columbia, Vancouver, British Columbia, Canada

⁷St Francis Xavier University, Antigonish, Nova Scotia, Canada

⁸BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada

⁹IBD Centre of BC, Vancouver, British Columbia, Canada

¹⁰Food Yourself, West Vancouver, Vancouver, British Columbia, Canada

25 Corresponding author: Kevan Jacobson, BC Children's Hospital Research Institute, University
26 of British Columbia, 950 West 28th Avenue, Vancouver, V5Z 4H4, Canada. Phone: +1 604 875
27 2332 extension 1, kjacobson@cw.bc.ca,

28

29 Abstract

30 *Introduction:* Inflammatory bowel disease (IBD), characterized by chronic intestinal
31 inflammation, can be subcategorized into Crohn's disease and ulcerative colitis. The
32 treatment for these conditions is unique to each patient, and may include lifestyle changes,
33 pharmaceutical intervention, and surgery. Lifestyle changes, such as dietary intervention,
34 are a cornerstone of IBD symptom management. Given the daily burden of this disease, self-
35 management is paramount in coping with and/or minimizing symptoms. The MyHealthyGut
36 application (app), successfully proven to be a self-management tool for celiac disease,
37 shows promise for use in an IBD patient population.

38 *Objective:* To undertake user testing to inform the development of an IBD-focused version
39 of the current MyHealthyGut app.

40 *Methods:* This study was undertaken between October 2021 and April 2022. Participants
41 included IBD patients and healthcare practitioners (HCPs) (physicians, registered dietitians
42 [RD], and registered nurses [RN]), using social media postings and convenience sampling.
43 Two RDs demonstrated how to use the current functions and features of the app with each
44 participant. Participants used the app for a 2-week period which was followed by
45 participation in a focus group or individual interview to provide feedback on the app.
46 Qualitative questionnaires, tailored to each patient category, were administered verbally
47 and feedback was recorded. Thematic analysis techniques were used for data quantification
48 and analysis.

49 *Results:* 15 participants were recruited and enrolled. Of these, 14 participants took part in
50 the focus group and/or individual interviews. The feedback suggested changes related to
51 clinical uses (e.g. incorporating information collected by the app into electronic medical
52 record systems), food and symptom tracking (e.g. the option to track water intake), ease of
53 use (e.g. the option to autofill food tracker with frequently consumed meals), and app
54 content (e.g. information about IBD treatments). All (100%) of participants reported that
55 they would either use the app themselves or recommend the app to patients, once their
56 suggestions were implemented.

57 *Conclusion:* Through user testing and feedback collection, priorities for app modification
58 were identified. Areas of modification in the app functions and features, ease of use, and
59 content were identified. Once updated to meet the needs of IBD patients, the
60 MyHealthyGut app may be a useful tool for IBD self-management.

61

62 Funding Source: Canadian Foundation of Dietetic Research

63

64 Keywords: Inflammatory bowel disease; digital health application; nutrition; symptomology;
65 user testing

66

67 Word count: 3064

68

69 Abbreviations: Inflammatory Bowel Disease (IBD), Health Care Practitioner (HCP), Registered
70 Dietitian (RD), Registered Nurse (RN) Crohn's Disease (CD), Ulcerative Colitis (UC), electronic
71 health (eHealth), MyHealthyGut (MHG), Celiac Disease (CeD), gluten free (GF), application
72 (app)

Conflicts of interest: K. Jacobson – Advisory board: Abbvie, Janssen, Amgen; Merck; Viatris; Mckesson Canada; Speaker’s bureau: Abbvie Janssen; Investigator-initiated research support: Janssen; Stock options: Engene.

Acknowledgements: We would like to take the opportunity to thank the patients and health care professionals that provided feedback on the MyHealthyGut app.

Introduction

Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation, broadly categorized into two types, Crohn’s disease (CD) and ulcerative colitis (UC). Typical IBD symptoms include diarrhea, abdominal pain, weight loss, and bloody stools. The etiology of IBD has not been fully elucidated however environmental factors, such as diet has been under the spotlight in IBD development and management in recent decades [4,5]. Multiple studies have shown evidence that a diet high in fibre, fish, fruits, and vegetables has a protective effect against IBD. Conversely, a typical western diet, characteristically rich in n-6 polyunsaturated fatty acids (PUFA) and low in fibre, is suggested to contribute to the onset of IBD [6, 7]. Moreover, the rise in IBD incidence in countries adopting westernized practices, such as Africa, Asia, and South America, further supports the potential impact of the western diet [8].

Though IBD is seen globally, the prevalence of IBD was found to be the highest in highly industrialized countries, including those in North America, Australasia, and parts of Europe [8]. In Canada, the prevalence of IBD in 2018 is 0.7% and is forecasted to increase to 1.0% by 2030 [9]. The IBD patient population grows in tandem with its financial burden on the

healthcare system, predominantly through prescription drugs, biological therapies, and hospitalizations [10]. These direct healthcare costs, defined as the cost of medically necessary services for each IBD patient, were estimated in 2018 to be \$14.6 billion (USD) and \$1.29 billion (CAD) in the US and Canada, respectively [10]. In addition to direct healthcare costs, indirect costs include those related to patient time off work (absenteeism), decreased productivity, the mental health burden of living with a chronic disease, and premature and long-term disability [10]. One solution to the costs of primary care to both IBD patients and the healthcare system is a greater emphasis and investment in self-management strategies.

With the rise of mobile phone users worldwide, the electronic health (eHealth) monitoring movement is at the forefront of disease prevention and self-management. The eHealth applications (app) developed for chronic disease management including diabetes, several types of cancer, and chronic obstructive pulmonary disease, have demonstrated efficacy through decreased hospitalization rates, healthcare costs, and increased patient sense of security, understanding of their condition, and convenience [11]. The established benefits of eHealth in chronic disease management show promise for use of a mobile app as a tool in IBD management. A focus group study conducted by Khan and colleagues (2016) highlighted the IBD patient's need for a tool with better symptom tracking, disease control assessment, medication adherence, physician feedback, objective setting, and education [12]. While the validation of the IBD management mobile app, HealthPROMISE, created based on Khan and colleagues study outcomes revealed a reduction in hospitalization and increased understanding of IBD, however, no significant change in IBD quality indicators such as bowel symptoms, emotional health, social function, and overall quality of life were seen [13].

Given the importance of diet in IBD management and the lack of scientific-based nutrient advice and analysis features in current IBD management mobile apps, there is a need for a diet-centred mobile app, providing dietary guidance and support to IBD patients.

MyHealthyGut (MHG) is a mobile app that was originally designed for celiac disease (CeD) self-management [14,15]. At present, the only treatment for CeD is a strict gluten-free (GF) diet [16]. The app was developed to provide guidance, diet and symptom tracking, and information to users, related to the GF diet and CeD. Although CeD and IBD have key distinctions (primarily in the way that CeD is gluten-induced immune-mediated enteropathy), they may share similar risk association, etiology and patient experience [17,18,19]. Given these similarities, we hypothesized that many of the functions and features of the original MHG app, such as diet and symptom self-monitoring tools, may be transferable and beneficial to IBD patients, once tailored to the disease. The purpose of this study is to investigate the ways in which the original MHG app can be modified and tailored to meet the needs of IBD patients and HCPs.

Methods

Recruitment

This project was completed between October 2021 - April 2022. We recruited participants using a flyer posted on social media and convenience sampling. Participants included IBD patients and HCPs specializing in IBD (i.e., registered dietitians [RD], physicians, and registered nurses [RN]).

145

146 *Ethics Approval*

147 The project was reviewed and approved by the Research Ethics Board of University of British
148 Columbia (H21-02662).

149

150 *Study design*

151 After completing the consent process, participants met with two RDs at the beginning of the
152 study period. Participants were guided through the app setup, as well as the key functions
153 and features of the app. Participants were instructed to test the app for a two-week period
154 and make note of what they liked or disliked about the app features and functions, as well
155 as any ideas for improvement. Following the app testing period, the study RDs interviewed
156 participants (grouped by type) in either a focus group or individual interview, guided by
157 questionnaires developed for the purposes of this study. Participants received a \$25.00 CAD
158 gift card to Amazon, to provide compensation for their participation in the study.

159

160 *Questionnaire development*

161 Three versions of an open-response qualitative interview-based questionnaire were
162 developed, specific to participant type (patient, physician, RD/RN), for feedback provision.
163 Common mHealth evaluation questionnaires, including SUS, TAM, and uMARS, were used as
164 resources in the development of our questionnaires [19].

165

166

167

168

169

170 Patient version (11 questions):

	Question
1	What was your first reaction to the app?
2	How easy was the app to use and what would make it easier?
3	Did anything about the app confuse you about the app?
4	What features did you like most about the app?
5	What features would you use least?
6	Are there any features you dislike?
7	What are the things that you would most like to improve about the app?
8	What other types of apps do you currently use to help you manage your health?
9	Do you currently have any favourite apps and/or features within an app that you'd like to see included in this one?
10	How likely are you to use the MyHealthyGut app to help you manage your IBD in the future and how often would you use it?
11	Would you feel comfortable using this app to capture information about your diet and health and share it with a research team and/or your HCPs?

171

172

173

174

175

176

177

178

179 Physician version (9 questions):

	Question
1	How often do you see your average patient?
2	Do you have a series of questions you ask your patients in order to understand their disease state?
3	How beneficial are disease activity indices in your practice and would it be beneficial if an app collected all components of that algorithm regularly to produce a score?
4	What are the key areas of concern for your patients when it comes to managing their IBD?
5	What are some functionalities an app would need in order to be beneficial to your practice?
6	Would it be valuable for the app to flag a pattern or the frequency of specific symptoms and suggest the patient seek medical attention?
7	Are there any new innovations related to self-management of IBD that you would like to see in an app like this?
8	Do you recommend any apps to your patients or their families, related to IBD self-management?
9	Are there any specific resources you recommend to your patients or their families, and if so, which ones?

180

181

182

183

184

185 RD/RN version (9 questions):

	Question
1	What are the key areas of concern for your patients when it comes to managing their IBD?
2	Do you recommend any apps to your patients or their families, related to IBD self-management?
3	What features of the MyHealthyGut app did you like most and think your patients would use most?
4	Are there any features you disliked about the app, or think your patients would use the least?
5	Any improvements that you would suggest for the symptom tracker? (6) What kind of educational content would you like to see within the app?
6	What kind of educational content would you like to see within the app?
7	Are there any features you think would be important for your patients to have within an app for IBD self-management?
8	Would you recommend this app if it were tailored to IBD self-management?
9	Would you find it useful if patients could share information about their diet and health through the app ahead of appointments?

186

187 *Data Analysis*

188 Conversations were recorded and transcribed by the interviewers. Thematic analyses were
189 performed in accordance with the Kiger and Varpio (2020) “Thematic analysis of qualitative
190 data: AMEE Guide No. 131”, and was completed as follows:

191 Step (1) *Familiarize yourself with the data*: The RDs reviewed the interview transcripts.

192 Step (2) *Generating initial codes*: Codes were created and defined to categorize the content

193 of each transcript.

194 Step (3) *Searching for themes*: Through completing steps 1 and 2, themes were identified

195 independently.

196 Step (4) *Reviewing themes*: The RDs reviewed the proposed themes together.

197 Step (5) *Defining and naming themes*: The identified themes were named and defined.

198 Step (6) *Producing the report/manuscript*: A report was created based on the analysis of the

199 frequency of each theme arising in the discussion and specific ideas or pieces of feedback

200 within each theme.

201

202 Results

203 *Participants*

204 A total of 15 participants (9 patients, 6 HCPs, including 2 MDs, 3 RDs, and 1 RN) were

205 recruited to participate. 14 participants provided feedback, however, 1 patient participant's

206 feedback was excluded, as it was related to the participant's person use of supplements and

207 was therefore unrelated to the objective of the study.

208

209 *Themes*

210 Feedback collected was grouped into 12 different themes, based on the type of comments

211 and answers received: 1) clinical use, 2) symptom management, 3) nutrition, 4)

212 medications/supplements, 5) parents/transitional phase, 6) customization, 7)

213 resources/education, 8) functionality, 9) accessibility, 10) community, 11) wellness, and 12)

214 research. **Table 1** summarizes the frequency of theme occurrence. In summary, the MDs

provided feedback most frequently about the clinical use theme. The RDs provided feedback most frequently about the nutrition, symptom management, and resources/education themes. The RN provided feedback most frequently about the nutrition and resources/education themes. The patients provided feedback most frequently about nutrition, symptom management, resources/education, and the functionality/ease of use themes.

The 12 themes were defined as follows:

- 1) *Clinical Use*: How a HCPs could use the app in their practice or to connect with their patients/other HCPs
- 2) *Symptom Management*: Any feedback or commentary related to symptoms, the symptom tracker, and/or symptom management
- 3) *Nutrition*: Any feedback or commentary related to nutrition for IBD and/or the food tracker
- 4) *Medications and Supplements*: Any feedback or commentary related to the use of medication or supplements for the prevention and treatment of symptoms of IBD and other conditions
- 5) *Parents/Transitional Phase*: Any feedback or commentary related to a parent using the app on behalf of their child with IBD
- 6) *Customization*: Any feedback or commentary related to the ability of each user to customize the app to meet their unique needs
- 7) *Resources/Education*: Any feedback or commentary related to topics of interest that could be included in the app as a source of information
- 8) *Functionality*: Any feedback or commentary related to the app ease of use

- 239 9) *Accessibility*: Any feedback or commentary related to barriers of accessibility to the app
- 240 10) *Community*: Any feedback or commentary related to related to ways in which users
- 241 could connect with others on the app
- 242 11) *Wellness*: Any feedback or commentary related to wellness outside of 'clinical' IBD
- 243 health (i.e., mental wellness, physical activity)
- 244 12) *Research*: Any feedback or commentary related to access to future research studies,
- 245 new advances in research, etc. through the app

246

247 *Table 1. Frequency of Theme Occurrence by Participant Type*

Themes	Physician (n=1)	RDs (n=3)	RN (n=1)	Patients (n=8)
Clinical use	14	9	2	12
Symptom Management	5	23	4	26
Nutrition	2	31	12	29
Medications/Supplements	0	14	4	3
Parents/Transitional Phase	0	0	3	1
Customization	0	7	5	14
Resources/Education	0	27	17	24
Functionality	0	12	6	29
Accessibility	0	10	0	6
Community	0	3	0	8
Wellness	0	12	0	7
Research	0	1	0	6

248

249 *Representative constructive feedback quotations for app modification*

- 250 1. "Definitely the meal and symptom tracker is what I geared most towards. I think if
251 there was a water tracking piece to it, that would've been better for me." - IBD
252 patient
- 253 2. "I didn't really use 'Ask a Question', but that's the only feature I didn't use." - IBD
254 patient
- 255 3. "[If the app had everything I wanted], the goal would be to use it once a day." - IBD
256 patient
- 257 4. "Breaking the food tracker down into times, rather than just meals [would improve
258 useability]." - IBD patient
- 259 5. "When I search for food [in the tracker], that's where I can imagine your typical day
260 already being there. And then it could ask 'Was it a typical day?' [and you'd respond]
261 'yes' or 'no'." - IBD patient
- 262 6. "I can see the safe food list being beneficial to our patients. Gluten is a problem for
263 some, but more so FODMAP and fibre content. Tagging insoluble vs. soluble fibre in
264 the list would be a super good resource." - RD
- 265 7. "As far as educational content, we talk a lot with patients about managing
266 symptoms. Things that as dietitians we can take for granted, such as eating small,
267 frequent meals." - RD
- 268 8. "It would be best if the results [from the app trackers] could be integrated into our
269 Electronic Medical Records" - Physician
- 270 9. "I would definitely [recommend the app to my patients if it were tailored to IBD]. It's
271 nice to have a one stop shop." - RD
- 272 10. "I would never delete the app if it had the function of communicating distressing
273 symptoms to my gastroenterologist" - IBD patient

274

275

276

277 *Application usability*

278 All participants (n=14) said that they would be eager to use and/or recommend an IBD-
279 focused self-management app if it came to fruition and reflected their suggestions.

280

281 Discussion

282 *Principal Results (Priorities)*

283 The most frequently mentioned theme sub-topics were identified and summarized, with the
284 intention of providing guidance for prioritization in the MHG app modification phase that
285 will follow on from this study. Identified priorities were divided into two groups: technical
286 priorities and content development priorities. Technical priorities included automation,
287 customization, food tracker improvements, symptom tracker improvements, and tracking
288 medications. Content development priorities included the development of various resources
289 and education, improving the language in the app, and creating recipes specific to common
290 IBD trigger foods.

291

292 *Strengths/Limitations*

293 A notable strength of this study was the enrolment of participants who either had IBD or
294 worked as a HCP in the IBD field. In doing this, we were able to collect feedback that was
295 very specific to the goal end user of the app. We were also able to capture two different
296 perspectives, the very specific perspective of the patient and the more general and widely

applicable perspective of the practitioner. This strategy will allow us to develop the IBD version of the app with user-centred design.

A limitation of the study is the small sample size (n=15). Recruitment was completed only through social media posting and word of mouth, due to financial limitations. With greater funding allocated to recruitment, more resources could have been put towards the strategy used, which could have elicited a larger sample size. Unfortunately, the limited sample in this study affects the generalizability of the results. Another notable limitation is the use of a CeD based app in the trial with an IBD population. When trialling the app, some of the features and functions were irrelevant to the study population. Therefore, participants' experience of the app was not as thorough as it would have been with IBD-tailored features. Finally, the study was undertaken during the COVID-19 pandemic, which impacted almost all aspects of everyday life, on a global scale. This may have affected recruitment, as well as the level of participant dedication.

Comparison with prior work

To our knowledge, this is the first study to user test a mobile app for modification as a nutrition therapy app for IBD patients. There are several eHealth platforms focusing on IBD patient education, diagnostic support, symptom management for clinical purpose, yet the outcomes for each study reveal inconsistent effects on IBD quality indicators [19, 21]. The MyHealthyGut app diet tracking feature along with the IBD symptom diary provides users with personalized diet associated patterns linking their food intake and symptoms, which provides an opportunity for more targeted treatment and better treatment efficacy.

A study by Villinger and colleagues (2019) demonstrated the poor long-term user adhesion to eHealth platforms, impacting prolonged beneficial outcomes [22]. App usability has been

identified as the barrier to long-term user engagement of nutrition app and food database tools in previous studies [23]. In this study, feedback on the usability of the app was assessed through questionnaires and priority changes for a more user-friendly design were identified.

Finally, previous eHealth platforms designed for IBD management have been assessed by IBD patients' satisfaction and healthcare activities in isolation, which excludes the view of the healthcare team [18, 23]. In this project, the HCPs in the IBD field were included as part of the assessment process and were also able to provide feedback for further app development.

Future Directions

Our future directions are to implement the identified priority changes to the existing MHG app. Once the new IBD version of MHG exists, the functions and features could be tested by users with similar methodology to the previously completed validation study [14]. We also intend to validate the food and symptom trackers so that they can be utilized in scientific research. Finally, there is potential for future variations of the app to exist for a multitude of other disease states.

Conclusion

With modifications to functionality and capabilities of the app, as well as the focus of the educational content, the current app is transferable to an IBD population. Responses from focus groups and interviews will be used to inform future modifications in the app. The proposed IBD self-management app would be of value to, and used or recommended by, both IBD patients and HCPs specializing in IBD.

346 References

- 347 1. Fakhoury M, Al-Salami H, Negrulj R, Mooranian A. Inflammatory bowel disease: clinical
348 aspects and treatments. JIR. Informa UK Limited; 2014. p. 113. doi: 10.2147/jir.s65979
- 349 2. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. The
350 Lancet. Elsevier BV; 2007. p. 1627–1640. doi: 10.1016/s0140-6736(07)60750-8
- 351 3. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the
352 pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. Springer Science and
353 Business Media LLC; 2017. p. 1–10. doi: 10.1007/s12328-017-0813-5
- 354 4. Turpin W, Goethel A, Bedrani L, Croitoru, MDCM K. Determinants of IBD Heritability:
355 Genes, Bugs, and More. Inflammatory Bowel Diseases. Oxford University Press (OUP);
356 2018. p. 1133–1148. doi: 10.1093/ibd/izy085
- 357 5. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, et al. Host–microbe
358 interactions have shaped the genetic architecture of inflammatory bowel disease. Nature.
359 Springer Science and Business Media LLC; 2012. p. 119–124. doi: 10.1038/nature11582
- 360 6. Serrano-Moreno C, Brox-Torrecilla N, Arhip L, Romero I, Morales Á, et al. Diets for
361 inflammatory bowel disease: What do we know so far? Eur J Clin Nutr. Springer Science
362 and Business Media LLC; 2022. p. 1222–1233. doi: 10.1038/s41430-021-01051-9
- 363 7. Caio G, Lungaro L, Caputo F, Zoli E, Giancola F, et al. Nutritional Treatment in Crohn's
364 Disease. Nutrients. MDPI AG; 2021. p. 1628. doi: 10.3390/nu13051628
- 365 8. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, et al. Worldwide incidence and
366 prevalence of inflammatory bowel disease in the 21st century: a systematic review of
367 population-based studies. The Lancet. Elsevier BV; 2017. p. 2769–2778. doi:
368 10.1016/s0140-6736(17)32448-0
- 369 9. Kaplan GG, Bernstein CN, Coward S, Bitton A, Murthy SK, et al. The Impact of
370 Inflammatory Bowel Disease in Canada 2018: Epidemiology. Journal of the Canadian
371 Association of Gastroenterology. Oxford University Press (OUP); 2018. p. S6–S16. doi:
372 10.1093/jcag/gwy054
- 373 10. Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, et al. The Impact of
374 Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services
375 Utilization. Journal of the Canadian Association of Gastroenterology. Oxford University
376 Press (OUP); 2018. p. S17–S33. doi: 10.1093/jcag/gwy055
- 377 11. Wang J, Wang Y, Wei C, Yao N, Yuan A, et al. Smartphone Interventions for Long-Term
378 Health Management of Chronic Diseases: An Integrative Review. Telemedicine and e-
379 Health. Mary Ann Liebert Inc; 2014. p. 570–583. doi: 10.1089/tmj.2013.0243
- 380 12. Khan S, Dasrath F, Farghaly S, Otober E, Riaz M, et al. Unmet Communication and
381 Information Needs for Patients with IBD: Implications for Mobile Health Technology.
382 BJMMR. Sciencedomain International; 2016. p. 1–11. doi: 10.9734/bjmmr/2016/21884
- 383 13. Zhen J, Marshall JK, Nguyen GC, Atreja A, Narula N. Impact of Digital Health Monitoring
384 in the Management of Inflammatory Bowel Disease. J Med Syst. Springer Science and
385 Business Media LLC; 2021. doi: 10.1007/s10916-021-01706-x
- 386 14. Dowd AJ, Warbeck CB, Tang KT, Fung T, Culos-Reed SN. MyHealthyGut: Findings from
387 a pilot randomized controlled trial on adherence to a gluten-free diet and quality of life
388 among adults with celiac disease or gluten intolerance. DIGITAL HEALTH. SAGE
389 Publications; 2020. p. 205520762090362. doi: 10.1177/2055207620903627
- 390 15. Dowd AJ, Jackson C, Tang KTY, Nielsen D, Clarkin DH, Culos-Reed SN. MyHealthyGut:
391 development of a theory-based self-regulatory app to effectively manage celiac disease.
392 mHealth. AME Publishing Company; 2018. p. 19–19. doi: 10.21037/mhealth.2018.05.05
- 393 16. Kleinjans M, Schneider CV, Bruns T, Strnad P. Phenome of coeliac disease vs.
394 inflammatory bowel disease. Sci Rep. Springer Science and Business Media LLC; 2022.
395 doi: 10.1038/s41598-022-18593-y
- 396 17. Pinto-Sanchez MI, Seiler CL, Santesso N, Alaedini A, Semrad C, Lee AR, Bercik P,
397 Lebwohl B, Leffler DA, Kelly CP, Moayyedi P, Green PH, Verdu EF. Association Between
398 Inflammatory Bowel Diseases and Celiac Disease: A Systematic Review and Meta-

399 Analysis. *Gastroenterology*. Elsevier BV; 2020. p. 884-903.e31. doi:
400 10.1053/j.gastro.2020.05.016

401 18. Mårild K, Söderling J, Lebowitz B, Green PHR, Pinto-Sanchez MI, Halfvarson J,
402 Roelstraete B, Olén O, Ludvigsson JF. Association of Celiac Disease and Inflammatory
403 Bowel Disease: A Nationwide Register-Based Cohort Study. *Am J Gastroenterol*; 2022.
404 p. 1471–1481. doi: 10.14309/ajg.0000000000001834

405 19. Zhen J, Marshall JK, Nguyen GC, Atreja A, Narula N. Impact of Digital Health Monitoring
406 in the Management of Inflammatory Bowel Disease. *J Med Syst*. Springer Science and
407 Business Media LLC; 2021. doi: 10.1007/s10916-021-01706-x

408 20. Hajesmaeel-Gohari S, Khordastan F, Fatehi F, Samzadeh H, Bahaadinbeigy K. The most
409 used questionnaires for evaluating satisfaction, usability, acceptance, and quality
410 outcomes of mobile health. *BMC Med Inform Decis Mak*. Springer Science and Business
411 Media LLC; 2022. doi: 10.1186/s12911-022-01764-2

412 21. Gerner M, Vuillerme N, Aubourg T, Messner E-M, Terhorst Y, Hörmann V, Ganzleben I,
413 Schenker H, Schett G, Atreja R, Neurath MF, Knitza J, Orlemann T. Review and
414 Analysis of German Mobile Apps for Inflammatory Bowel Disease Management Using the
415 Mobile Application Rating Scale: Systematic Search in App Stores and Content Analysis.
416 *JMIR Mhealth Uhealth*. JMIR Publications Inc.; 2022. p. e31102. doi: 10.2196/31102

417 22. Villinger K, Wahl DR, Boeing H, Schupp HT, Renner B. The effectiveness of app-based
418 mobile interventions on nutrition behaviours and nutrition-related health outcomes: A
419 systematic review and meta-analysis. *Obesity Reviews*. Wiley; 2019. p. 1465–1484. doi:
420 10.1111/obr.12903

421 23. König LM, Attig C, Franke T, Renner B. Barriers to and Facilitators for Using Nutrition
422 Apps: Systematic Review and Conceptual Framework. *JMIR Mhealth Uhealth*. JMIR
423 Publications Inc.; 2021. p. e20037. doi: 10.2196/20037